Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews

Like the Progress Educational Trust on Facebook


 


 

Multigene testing proves useful for breast and ovarian cancer

17 August 2015

By Dr Nicoletta Charolidi

Appeared in BioNews 815

Researchers have found that tests for multiple breast and ovarian cancer risk genes can be used to inform treatment decisions for women with personal or family history for such cancers.

Over 13 years, researchers from Massachusetts General Hospital (MGH), Stanford University and Beth Israel Deaconess Medical Center used multigene panel screens in 1069 women to look for non-BRCA1 or BRCA2 mutations.

The women who took part in the study were chosen because of their personal or family history in breast and ovarian cancers. Their samples were tested either with a 25- or 29-gene panel.

The findings, published in JAMA Oncology, showed that 40 women, or 3.8 percent of the total group, carried potentially harmful mutations. Twenty-six of these mutations were associated with low-to-moderate risk of breast or ovarian cancer, eight with Lynch syndrome, which is linked to colon and ovarian cancer risk, and three to other high-risk breast cancer genes (including CDH1 and PALB2).

Lead author Leif Ellisen, professor of medicine at Harvard Medical School, commented, 'If you actually look on a case-by-case basis, in the majority of women where you find these mutations, you really would change what you recommend to them for either screening or prevention of cancer based on finding that genetic information.'

He added: 'Even among all appropriate candidates who are sent for genetic testing, only nine percent will test positive for the BRCA mutations, so an additional four percent who have non-BRCA mutations is a significant number.'

Overall, including 23 women that were recruited later in the study, there were 63 non-BRCA mutations. In 33 of these cases, the researchers recommended additional screening and preventive surgery. In addition, risk calculation for the presence of these mutations recommended that close female family members for 72 percent of these cases should also be screened.

However, some experts have expressed concerns about multigene testing, based on the fact that we might not be ready for incorporating poorly defined cancer mutations into clinical practice.

Dr Elizabeth Swisher, an obstetrics and gynaecology researcher from the University of Washington who wrote a commentary accompanying the study, noted a 'major argument against multigene testing has been the need to avoid harm by providing mutation information on genes for which guidelines about care management are not well defined'.

However, she concluded, 'We must continue to assess the effect of such tests on clinical care and patient experience... and work to provide meaningful guidelines for cancer-preventive care for those with less common genetic findings.'

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

12 September 2016 - by Anastassia Bolotkova 
The FDA has warned that it does not recommend the use of any currently available ovarian cancer screening tests to detect the disease...
09 May 2016 - by Rachel Siden 
Adding more genes to existing multi-gene panels that test for breast and ovarian cancer risk offers little clinical benefit, a study says...
25 January 2016 - by Isobel Steer 
Scientists have identified a mutation in the gene BRIP1 that triples a woman's risk of ovarian cancer...
11 January 2016 - by Dr Lucy Freem 
A study involving more than 200,000 Nordic twins has found that cancer is 33 percent heritable...
09 November 2015 - by Ayala Ochert 
Scientists say it may be possible to track the progress of cancer – and cancer treatment – in real time from fragments of tumour DNA that are shed into the bloodstream...

08 June 2015 - by Jenny Sharpe 
Researchers have called for mass screening of women in their 30s to detect cancer-causing mutations...
27 April 2015 - by Dr Indrayani Ghangrekar 
A US company has announced a low-cost genetic test for breast cancer...
30 March 2015 - by Sophie McLachlan 
In an article in the New York Times, Angelina Jolie has revealed her decision to have her ovaries and fallopian tubes removed, in her on-going battle to reduce her risk of cancer...
22 September 2014 - by Jessica Ware 
The number of women in the UK being referred to breast cancer clinics doubled shortly after actress Angelina Jolie revealed she had a risk-reducing double mastectomy, a study has found....
11 August 2014 - by Dr Kimberley Bryon-Dodd 
A new study suggests that mutations in a gene called PALB2 are just behind BRCA1 and BRCA2 mutations as a leading genetic risk factor for breast cancer...

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions


- click here to enquire about using this story.

Published by the Progress Educational Trust

CROSSING FRONTIERS

Public Conference
London
8 December 2017

Speakers include

Professor Azim Surani

Professor Magdalena Zernicka-Goetz

Professor Robin Lovell-Badge

Sally Cheshire

Professor Guido Pennings

Katherine Littler

Professor Allan Pacey

Dr Sue Avery

Professor Richard Anderson

Dr Elizabeth Garner

Dr Andy Greenfield

Dr Anna Smajdor

Dr Henry Malter

Vivienne Parry

Dr Helen O'Neill

Dr César Palacios-González

Philippa Taylor

Fiona Fox

Sarah Norcross

Sandy Starr


BOOK HERE

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation